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Background: Antiretroviral therapy (ART) restores immune function and reduces HIV-related 
adverse outcomes. But treatment failure erodes this advantage and leads to an increased morbid-
ity and compromised quality of life in HIV patients. The aim of this study was to determine the 
prevalence and factors associated with first-line ART failure in HIV patients at the University 
of Gondar Teaching Hospital.
Patients and methods: A retrospective study was conducted on 340 adults who had started 
ART during the period of September 2011 to May 2015. Data regarding patients’ sociodemo-
graphics, baseline characteristics, and treatment-related information were collected through 
review of their medical charts. Data were analyzed using SPSS version 21. Descriptive statis-
tics, cross-tabs, and binary and multiple logistic regressions were utilized. P<0.05 was used to 
declare association.
Results: Among the 340 patients enrolled, 205 were females (60.3%). The mean age at ART 
initiation was 34.4 years. A total of 14 (4.1%) patients were found to have treatment failure. The 
median duration of treatment failure from initiation of treatment was 17.5 months (8–36 months). 
Poor adherence to treatment and low baseline CD4 cell count were found to be significant 
predictors of treatment failure.
Conclusion: The prevalence of first-line ART failure was 4.1%. Treatment failure was most 
likely to occur for the patients who had poor drug adherence and those who were delayed to 
start ART till their CD4 cell count became very low (<100 cells/mm3).
Keywords: treatment failure, antiretroviral drugs, risk factor, adherence
Introduction
Human immunodeficiency virus (HIV) is responsible for a worldwide pandemic, 
and it is the cause of acquired immune deficiency syndrome (AIDS).1 According to 
UNAIDS report on the Global AIDS Epidemic in 2012, there were 35.3 million people 
living with HIV. In addition, 2.3 million people became newly infected with HIV and 
1.6 million people died from AIDS-related illnesses in the same year.2,3
Over the past decade, there has been an unparalleled effort to provide access to 
antiretroviral therapy (ART) for HIV-infected individuals in sub-Saharan Africa, the 
region with the highest HIV burden.4 ART restores immune function and reduces HIV-
related adverse outcomes. Since the beginning of highly active antiretroviral therapy 
(HAART) in 1996, there have been dramatic declines in morbidity and mortality due to 
HIV.5 This advantage is eroded when treatment failure develops. Despite the significant 
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reduction in morbidity and mortality among the HIV-infected 
patients receiving combination ART, a considerable number 
of patients fail to achieve a sustained virological and immu-
nological response to therapy.6
Treatment failure can be defined as progression of dis-
ease after initiation of HAART. Failure can be assessed by 
clinical (the appearance of new opportunistic infections, 
ongoing weight loss, etc), immunologic (a decline in CD4 
count), or virologic (a viral rebound above a set threshold of 
200  copies/mL) criteria.7
Viral load monitoring has become the standard of care 
for monitoring the success of and diagnosing the failure of 
ART and has been explicitly recommended, when available, 
by the World Health Organization (WHO) since 2010.8,9 
In settings in which there is no access to viral load testing, 
clinical monitoring alone or a combination of clinical and 
immunologic monitoring is used to assess response to ART 
and determine treatment failure.10
The patients who had failed for first-line drug are 46% 
more likely to fail again for second-line drugs and are attrib-
uted to the higher number of side effects and have greater like-
lihood of experiencing drug resistance and treatment fatigue 
as a result of being on treatment longer.11 The development 
of drug-resistant virus strains can be another threat if this 
virus starts to transmit in the population.12,13 Early detection 
of treatment failure is crucial to sustain the effectiveness of 
the first-line therapy.14,15
Studies in East Africa have shown a high prevalence of 
immunologic failure ranging from 8% to 57% among cli-
ents on first-line HAART, and furthermore, the magnitude 
increases as the time of follow-up increases.6,16,17
The immunological failure rate in Ethiopia was found 
to be high. The study conducted at Debremarkos Hospital 
showed that 21% of the HIV patients had developed immu-
nological failure with a failure rate of eight per 100 patient-
years of follow-up.18
The timing and accuracy of identifying treatment failure 
in resource-limited settings are fundamental but challenging. 
Delayed detection of treatment failure may increase drug 
toxicity, may lead to the accumulation of drug resistance-
associated mutations (further limiting treatment options), 
and may result in increased morbidity and mortality.
The documented factors associated with treatment failure 
include, but are not limited to: sociodemographic factors 
(eg, age, sex, being an orphan), baseline clinical factors 
(eg, high pretreatment viral load, low pretreatment CD4 
count, prior WHO stage), drug–drug interactions (between 
the ART and concomitantly administered drugs), drug side 
effects, drug toxicity or inadequate adherence to treatment, 
poor adherence, certain ART regimen combinations, primary 
infection with drug-resistant strains of HIV, prior exposure to 
antiretroviral monotherapy, high baseline plasma viral load, 
and low baseline CD4 count.19–25
The objective of this study was to determine the preva-
lence of first-line ART failure and to identify those risk fac-
tors that contribute to treatment failure in the Ethiopian HIV 
patients. Identification of risk factors helps to define early 
predictors of treatment efficacy that permit better use of these 
potent drugs, avoid unnecessary side effects of second-line 
drug, prevent drug resistance, and decrease economic burden, 
especially in a resource-limited setting like Ethiopia due to 
the expensiveness of the second-line drug. It will also help 
as a guide for health professionals and higher officials to 
alleviate the problem and to develop strategies to decrease 
the rate of treatment failure.
Patients and methods
This retrospective record review study was conducted on 340 
HIV patients who started ART in the period of September 
2011–May 2015 at the University of Gondar Teaching Hos-
pital, Northwest Ethiopia. The hospital serves for ~4 million 
people in the region. It has >400 beds. The ART Clinic was 
established in 2003, and a total of 9,390 clients started ART 
since its establishment. There were 5,138 active patients on 
ART at the time of this study. This study was conducted from 
April 20, 2015 to May 19, 2015. Those patients who were 
younger than 18 years old and those who took antiretroviral 
drugs for <6 months were excluded from this study. The 
patients were included in this study using simple random 
sampling method.
The data were collected by reviewing patients’ medical 
charts. Data abstraction format was developed after reviewing 
studies conducted on the topic, and it was pretested on 5% of 
the sample population on one of the private hospital found 
in the Gondar town. The data abstraction format contained 
patient sociodemographics, baseline characteristics, treat-
ment-related data, and treatment failure-related information. 
Data were collected by four pharmacists who were trained for 
2 days on the documentation and techniques of data collection.
Data were checked for its completeness everyday. They 
were edited, cleaned, and analyzed. The collected data were 
entered into Epi Info 7 and analyzed using SPSS version 21 
(IBM Corporation, Armonk, NY, USA). Cross-tabulation was 
used in bivariate analysis. A test of association was done using 
binary logistic regression. P-value <0.05 was  considered 
 significant. The results of this study were organized in the 
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form of frequencies and percentages. The data were sum-
marized and described using text and tables.
Ethical clearance was obtained from the research ethi-
cal review board of the School of Pharmacy, University of 
Gondar. A formal letter of permission was also obtained from 
the University of Gondar Teaching Hospital Administration. 
Patient information obtained from the charts was kept confi-
dential. Thus, patient identifiers such as name and address of 
the patient were not recorded in the data abstraction format. 
The ethics committee of the School of Pharmacy, Univer-
sity of Gondar did not require written informed consent be 
obtained from all patients, as this was a retrospective study, 
and all data was anonymous.
Results
Sociodemographic characteristics of 
patients
As indicated in Table 1, out of 340 patients included in this 
study, nearly three out of five (60.3%) patients were females. 
The mean age of patients at the start of ART was 34.4 years 
(range 19–67 years). Seventy-eight (22.9%) of the study 
participants had no formal education, and 121 (35.6%) of 
them had a history of substance abuse, of which the majority 
of them used alcohol (68%) and tobacco (30%).
Baseline clinical characteristics of patients
The mean CD4 count at ART initiation was 212.7 cells/mm3 
(range 6–704 cells/mm3). Table 2 shows that the majority of 
the patients start ART when their clinical status was at WHO 
stage 3. One hundred sixty (47.1%) patients had one or more 
opportunistic infection at the time of their ART initiation. 
The majority of the patients, 323 (95.0%) were working 
by their functional status, and 32 (9.4%) had significant 
comorbid illness at the start of ART.
Treatment-related information
Most of the patients were either on zidovudine–lamivudine–
nevirapine (40%) or tenofovir–lamivudine–efavirenz regimen 
(34.1%). Approximately 87% of the study subjects followed 
their treatment for >12 months. Majority of the patients, 326 
(95.9%), had good adherence to their treatment. The detail 
on treatment-related information is found in Table 3.
Treatment failure
A total of 14 (4.1%) patients were found to have treatment 
failure. The average duration between the initiation of treat-
ment and recognition of treatment failure was 17.5 months 
(8–36 months). As shown in Table 4, majority of treatment 
Table 1 Sociodemographic characteristics of HIV/AIDS patients 
on antiretroviral therapy at UGTH, Northwest Ethiopia, May 
2015
Variables Categories Frequency (%)
Sex Female 205 (60.3)
Male 135 (39.7)
Age (years) 18–30 140 (41.2)
31–45 173 (50.9)
46–60 24 (7.1)
>60 3 (0.9)
Marital status Never married 52 (15.3)
Married 171 (50.3)
Divorced 67 (19.7)
Widowed 29 (8.5)
Separated 21 (6.2)
Religion Orthodox 306 (90)
Protestant 3 (0.9)
Muslim 31 (9.1)
Educational status No education 78 (22.9)
Primary education 90 (26.5)
Secondary education 126 (37.1)
Higher education 46 (13.5)
Substance abuse No 219 (64.4)
Yes 121 (35.6)
Abbreviations: UGTH, University of Gondar Teaching Hospital; HIV, human 
immunodeficiency virus; AIDS, acquired immune deficiency syndrome.
Table 2 Baseline clinical characteristics of HIV/AIDS patients 
on antiretroviral therapy at UGTH, Northwest Ethiopia, May 
2015
Variables Categories Frequency (%)
Initial CD4 cell count (cells/mm3) <50 23 (6.7)
50–100 53 (16)
101–199 98 (29.7)
200–349 105 (31.8)
350–500 41 (12.4)
>500 10 (2.9)
WHO staging at initiation of ART Stage 1 91 (26.8)
Stage 2 83 (24.4)
Stage 3 139 (40.9)
Stage 4 27 (7.9)
Presence of opportunistic infections No 180 (52.9)
Yes 160 (47.1)
Weight (kg) <35 2 (0.6)
35–50 142 (41.8)
51–65 165 (48.5)
>65 31 (9.1)
Significant comorbid illness No 308 (90.6)
Yes 32 (9.4)
Functional status Working 323 (95)
Ambulatory 14 (4.1)
Bed ridden 3 (0.9)
AIDS-defining illness prior to ART No 180 (52.9)
Yes 160 (47.1)
Abbreviations: HIV, human immunodeficiency virus; AIDS, acquired immune 
deficiency syndrome; UGTH, University of Gondar Teaching Hospital, WHO, 
World Health Organization; ART, antiretroviral therapy.
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Table 3 Treatment-related information of HIV/AIDS patients on 
antiretroviral therapy at UGTH, Northwest Ethiopia, May 2015
Variables Categories Frequency (%)
Initial first-line ART regimen D4T/3TC/NVP 5 (1.5)
D4T/3TC/EFV 4 (1.2)
AZT/3TC/NVP 136 (40)
AZT/3TC/EFV 39 (11.5)
TDF/3TC/EFV 116 (34.1)
TDF/3TC/NVP 39 (11.5)
Months on ART 6–12 43 (12.7)
>12 297 (87.4)
Adherence to first-line regimena Good 326 (95.5)
Fair 5 (1.5)
Poor 9 (2.6)
History of treatment interruption No 132 (97.6)
Yes 8 (2.4)
Months of interruption <6 7 (87.5)
6–12 1 (12.5)
Note: aTotal doses taken/total doses prescribed ×100: good (>95% adherence 
level), fair (85%–94% adherence level), and poor (<85% adherence level).
Abbreviations: HIV, human immunodeficiency virus; AIDS, acquired immune deficiency 
syndrome; UGTH, University of Gondar Teaching Hospital; ART, antiretroviral therapy; 
NVP, neverapin; EFV, efavirenz; AZT, zidovudine; TDF, tenofovir; D4T, stavudine; 3TC, 
lamivudine.
Drug nonadherence was the strongest risk factor for 
treatment failure as the patients with poor adherence to treat-
ment were >70 times more likely to have treatment failure 
when compared to the patients with good adherence to treat-
ment (adjusted odds ratio 70.54, 95% confidence interval 
5.57–893.86). Similarly when compared to the patients with 
baseline CD4 cell count >100 cells/mm3, the patients who had 
a baseline CD4 cell count <50 cells/mm3 and 50–100 cells/mm3 
were 16.7 and 9.1 times more risky to develop treatment fail-
ure, respectively, showing that lower baseline CD4 cell counts 
were associated with higher risk of treatment failure (Table 5).
Discussion
The identification and management of first-line ART failure 
is a key challenge for HIV programs in resource-limited 
 settings. Staying on a failing first-line therapy is associated 
with an increased risk of mortality. In addition to this, devel-
opment of drug resistance limits the ability to construct new, 
potent, and tolerable regimens in the future. This study was 
aimed to determine the prevalence of first-line ART failure 
and factors associated with it.
This study showed that first-line ART failure rate was 
4.1%, which is a closer result with the finding in a study 
conducted in Tanzania in which the failure rate was 7% and 
a study conducted in South Africa that reported a failure rate 
of 2.1%.26,27 However, this result was much lower than what 
was found in the study at Debremarkos Hospital, Ethiopia, 
in which the failure rate was reported as 21%.6 This larger 
gap may be due to the fact that most (95%) of the patients in 
this study had good adherence to their ART than the patients 
in the study at Debremarkos Hospital.
Even though the binary logistic regression showed many 
variables to have significant association with ART failure, 
multivariate logistic regression indicates that only poor 
adherence and low baseline CD4 cell count have strongest 
association with treatment failure. Similarly, the study 
conducted at Chiang Mai University Hospital, Thailand, 
showed that lower baseline CD4 cell count was one of the 
main factors significantly associated with ART failure.28
It was found that adherence is the independent predict-
ing factor for treatment failure and the patients with poor 
drug adherence were found to be 70.5 times at higher risk 
of developing treatment failure compared to the patients 
with good adherence to treatment. Although adherence has 
been demonstrated to be important in many studies, there 
is discordance of results depending on the types of adher-
ence measurement.22,26,27 In our study, the data on adherence 
were collected from the chart that was recorded according 
to the patient’s self-report of the amount of medication 
Table 4 Treatment failure after initiation of HAART in HIV/AIDS 
patients at UGTH, Northwest Ethiopia, May 2015
Variables Categories Frequency (%)
Presence of treatment failure No 326 (95.9)
Yes 14 (4.1)
Type of treatment failure Virologic failure 12 (85.7)
Immunologic failure 13 (92.9)
Failing regimen backbone 3TC + AZT 3 (21.4)
3TC + TDF 11 (78.6)
Months from ART initiation  
to second-line ART
6–12
>12
6 (42.9)
8 (57.1)
Abbreviations: HAART, highly active antiretroviral therapy; HIV, human immuno-
deficiency virus; AIDS, acquired immune deficiency syndrome; UGTH, University 
of Gondar Teaching Hospital; 3TC, lamivudine; AZT, zidovudine; TDF, tenofovir; 
ART, antiretroviral therapy.
failure cases were on a regimen with lamivudine + tenofovir 
backbone. In most of the cases, the patients had both virologic 
and immunologic failure.
Factors associated with treatment failure
Table 5 indicates that advanced WHO stage, bedridden 
baseline functional status, treatment interruption, poor 
adherence, presence of opportunistic infections, and low 
baseline CD4 count (<100 cells/mm3) were found to be sig-
nificant predictors of treatment failure in the binary logistic 
regression analysis. But in multivariate logistic regression, 
only poor adherence and low baseline CD4 cell count were 
found to be significant predictors of the presence of treat-
ment failure.
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taken between visits without standardized set of questions. 
 Therefore, the result may not be completely reliable. How-
ever, it is still demonstrated to be an independent factor for 
treatment failure, as good drug adherence is the major fac-
tor to control the viral replication rate and achieve a good 
improvement in patient’s immunity.
This study found that the patients with an initial CD4 
cell count of <50 cells/mm3 and 50–100 cells/mm3 have 16.7 
and 9.1 times more risk of developing treatment failure than 
the patients with a higher baseline CD4 count, respectively. 
This study also found that all the failing patients had a CD4 
cell count of <200 cells/mm3 at baseline. This might be due 
to the reason that the patients with a low baseline CD4 cell 
count have a lesser immunity that may favor the probability 
of developing immunological failure. Similarly, a study in 
Ethiopia at Debremarkos University indicated that baseline 
CD4 count ≤100 cells/mm3 (adjusted hazard ratio 2.16, 95% 
confidence interval 1.44–3.25) is a significant predictor of 
immunological failure.6
Study limitation
This is a retrospective chart review study. The accuracy of 
analysis depends on the completeness of data and being ret-
rospective may also limit the study to find out more predictors 
of treatment failure than those recorded in the charts. Being a 
single-centered study, the result may not also be generalized 
to all hospitals. Thus, we suggest further prospective and 
multicentered studies to be done.
Conclusion
We conclude from this study that the first-line ART failure 
rate was 4.1%. Treatment failure was most likely to occur 
for the patients who had poor drug adherence and those who 
were delayed to start ART till their CD4 cell count became 
very low (<100 cells/mm3).
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